150 related articles for article (PubMed ID: 32937648)
1. B cell-activating factor (BAFF) in children with inflammatory bowel disease.
Fodor I; Serban O; Serban DE; Farcau D; Man SC; Dumitrascu DL
Pediatr Res; 2021 May; 89(7):1798-1803. PubMed ID: 32937648
[TBL] [Abstract][Full Text] [Related]
2. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
[TBL] [Abstract][Full Text] [Related]
3. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
Fu Y; Wang L; Xie C; Zou K; Tu L; Yan W; Hou X
Sci Rep; 2017 Jun; 7(1):2669. PubMed ID: 28572616
[TBL] [Abstract][Full Text] [Related]
4. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
Shentova R; Baycheva M; Kofinova D; Hadjiiski P; Yaneva P
Folia Med (Plovdiv); 2020 Jun; 62(2):271-275. PubMed ID: 32666743
[TBL] [Abstract][Full Text] [Related]
5. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
6. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
8. Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease.
van Gaal N; Lakenman R; Covington J; Savage R; de Groot E; Bomers M; Benninga M; Mulder C; de Boer N; de Meij T
J Breath Res; 2017 Nov; 12(1):016006. PubMed ID: 28439048
[TBL] [Abstract][Full Text] [Related]
9. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
[TBL] [Abstract][Full Text] [Related]
10. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
Boon GJ; Day AS; Mulder CJ; Gearry RB
World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
[TBL] [Abstract][Full Text] [Related]
11. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases.
Roszak D; Gałęcka M; Cichy W; Szachta P
Adv Med Sci; 2015 Sep; 60(2):246-52. PubMed ID: 25989184
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort.
Xie C; Quan R; Wang L; Chen C; Yan W; Fu Y
Clin Exp Immunol; 2019 Nov; 198(2):131-140. PubMed ID: 31314927
[TBL] [Abstract][Full Text] [Related]
14. Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease.
Kolho KL; Pessia A; Jaakkola T; de Vos WM; Velagapudi V
J Crohns Colitis; 2017 Mar; 11(3):321-334. PubMed ID: 27609529
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion.
Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M
Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807
[TBL] [Abstract][Full Text] [Related]
16. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease.
Aomatsu T; Imaeda H; Matsumoto K; Kimura E; Yoden A; Tamai H; Fujiyama Y; Mizoguchi E; Andoh A
Aliment Pharmacol Ther; 2011 Oct; 34(8):941-8. PubMed ID: 21848856
[TBL] [Abstract][Full Text] [Related]
17. Faecal Volatile Organic Compound Analysis in De Novo Paediatric Inflammatory Bowel Disease by Gas Chromatography-Ion Mobility Spectrometry: A Case-Control Study.
Vermeer E; Jagt JZ; Stewart TK; Covington JA; Struys EA; de Jonge R; de Boer NKH; de Meij TGJ
Sensors (Basel); 2024 Apr; 24(9):. PubMed ID: 38732837
[TBL] [Abstract][Full Text] [Related]
18. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.
Kumric M; Zivkovic PM; Ticinovic Kurir T; Vrdoljak J; Vilovic M; Martinovic D; Bratanic A; Lizatovic IK; Bozic J
Diagnostics (Basel); 2021 Dec; 12(1):. PubMed ID: 35054212
[TBL] [Abstract][Full Text] [Related]
19. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
[TBL] [Abstract][Full Text] [Related]
20. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
